Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1060850

	registered interest
	date	13/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Air Pollution: Children
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary State for Health and Social Care, what assessment he has made of the effect of toxic air on children’s health.
	tabling member constituency	Scunthorpe
	tabling member printed	Nic Dakin
	uin	220891
	answer	answer is ministerial correction date of answer 18/02/2019 answer text <p>Poor air quality is the largest environmental risk to public health in the United Kingdom. Long-term exposure to air pollution can cause chronic conditions such as cardiovascular, respiratory diseases and cancer, leading to reduced life expectancy.</p><p> </p><p>Air pollution has a particular impact on children as they grow. There is evidence that the process of normal lung function growth in children is suppressed by long-term exposure to air pollution.</p><p> </p><p>The effects of air pollution on children’s health are being studied in research projects. The EXHALE Programme is a London study on air pollution and children’s lung health. The Committee on the Medical Effects of Air Pollutants has started work to consider the evidence for the effects of air pollution on adverse birth outcomes. The Royal College of Paediatrics and Child Health is working on a report on ‘Indoor Air Quality on Children and Young People’s Health across the Life Course’.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/02/2019 17:13:48 answering member 4067 label Biography information for Steve Brine
	tabling member	4056 label Biography information for Nic Dakin

828793

	registered interest
	date	23/01/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Kidney Diseases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State Health and Social Care, what steps his Department is taking to ensure that chronic kidney disease is diagnosed in a timely manner.
	tabling member constituency	Sunderland Central
	tabling member printed	Julie Elliott
	uin	124425
	answer	answer is ministerial correction date of answer 31/01/2018 answer text <p>The National Institute for Health and Care Excellence guidance Chronic kidney disease in adults: assessment and management, updated in July 2014, sets out best practice for clinicians in the diagnosis and management of chronic kidney disease (CKD). The guidance covers identification and monitoring of patients at risk; pharmacological management and referral where appropriate, and aims to ensure patients remain healthy and avoid kidney failure, if possible. The guidance can be found at the following link:</p><p> </p><p><a href="http://www.nice.org.uk/guidance/cg182" target="_blank">www.nice.org.uk/guidance/cg182</a></p><p> </p><p>The NHS Health Check is a national programme (launched in 2009) for everyone between the ages of 40-74 years (not already on a chronic disease register) that assesses people’s health and risk of developing certain health problems. At launch it was estimated that the programme could detect each year at least 20,000 cases of diabetes or kidney disease earlier, allowing individuals to be better managed and to improve their quality of life. The first major evaluation of the NHS Health Check, published in 2016 and covering 665 general practitioner practices, demonstrated positive results, estimating that over the first five years it has identified a new case of chronic kidney disease in every 265 appointments. More information on the evaluation and its findings can be found be found at the following link:</p><p> </p><p><a href="http://www.gov.uk/government/news/first-national-evaluation-of-nhs-health-check-programme-published" target="_blank">www.gov.uk/government/news/first-national-evaluation-of-nhs-health-check-programme-published</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 31/01/2018 12:33:04 answering member 4067 label Biography information for Steve Brine
	tabling member	4127 label Biography information for Julie Elliott

850291

	registered interest
	date	26/02/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Alcoholic Drinks: Misuse
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care how many alcohol attributable hospital admissions there have been in each of the last three years; and if he will publish that information by (a) sex and (b) age group.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	129859
	answer	answer is ministerial correction date of answer 01/03/2018 answer text <p>Public Health England regularly publishes information showing the number of alcohol-related National Health Service hospital admissions in England in the Local Alcohol Profiles for England. The table below shows figures for the last three years based on primary and secondary diagnoses (broad measure):</p><table><tbody><tr><td><p> </p></td><td><p>Total</p></td><td><p>Male (all ages)</p></td><td><p>Female (all ages)</p></td></tr><tr><td><p>2016/17</p></td><td><p>1,135,710</p></td><td><p>732,790</p></td><td><p>402,920</p></td></tr><tr><td><p>2015/16</p></td><td><p>1,119,020</p></td><td><p>721,340</p></td><td><p>397,680</p></td></tr><tr><td><p>2014/15</p></td><td><p>1,078,810</p></td><td><p>695,360</p></td><td><p>383,450</p></td></tr></tbody></table><p> </p><p>This data, including a further breakdown by sex and age group is available at:</p><p> </p><p><a href="http://fingertips.phe.org.uk/documents/LAPE_Statistical_Tables_for_England_022018.xlsx" target="_blank">http://fingertips.phe.org.uk/documents/LAPE_Statistical_Tables_for_England_022018.xlsx</a></p><p> </p><p>NHS Digital will also publish this data in its annual Statistics on Alcohol 2018 report which is due to be published on 1 May.</p><p> </p><p>Data on the number of hospital bed days used by patients with alcohol-related conditions is not collected centrally.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 129860 question first answered 01/03/2018 15:49:41 answering member 4067 label Biography information for Steve Brine
	tabling member	1439 label Biography information for Norman Lamb

917381

	registered interest
	date	05/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Ibrutinib
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care how many people have received Ibrutinib on the NHS for the treatment of relapsed or refractory chronic lymphocytic leukaemia since January 2017.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	150007
	answer	answer is ministerial correction date of answer 13/06/2018 answer text <p>The information requested is not available. The number of patients registered to receive treatment with ibrutinib for relapsed or refractory chronic lymphocytic leukaemia between 1 January 2017 and 31 May 2018 was 976. Patients registered to receive a treatment do not then necessarily go on to receive treatment with a drug.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 13/06/2018 15:32:47 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

964583

	registered interest
	date	03/09/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care on what conditions Cancer Alliances will receive (a) 25 per cent, (b) 50 per cent and (c) 75 per cent of their cancer transformation funding bids in 2018-19.
	tabling member constituency	Mitcham and Morden
	tabling member printed	Siobhain McDonagh
	uin	168953
	answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>Cancer Alliances locally own their delivery plans, and it is the responsibility of each Alliance to publish these plans. NHS England encourages all Alliances to publish their plans, and where Alliances’ plans are already readily available, NHS England will signpost to these on its website.</p><p>The level of transformation funding received by each Cancer Alliance in 2018/19 is linked to their performance against the 62-day cancer waiting times standard as this is an important measure of a system’s readiness to implement significant transformation at pace and scale.</p><p>Where an Alliance is meeting the standard, they will receive 100% of their transformation funding allocation. For Alliances who are not meeting the standard, they will receive a proportion of their transformation funding, dependent on their level of performance. This is as follows:</p><p>- For an Alliance with a 62-day performance between 83% - 84.9%, they will receive 85% of their transformation funding allocation;</p><p>- For an Alliance with a 62-day performance between 80% - 82.9%, they will receive 75% of their transformation funding allocation; and</p><p>- For an Alliance with a 62-day performance of less than 80%, they will receive 50% of their transformation funding allocation.</p><p>More information about the levels of transformation funding received by each Cancer Alliance in 2018/19 can be found on NHS England’s website at the following link:</p><p><a href="https://www.england.nhs.uk/cancer/improve/cancer-alliances-improving-care-locally/nhs-england-support-and-funding-for-cancer-alliances/" target="_blank">https://www.england.nhs.uk/cancer/improve/cancer-alliances-improving-care-locally/nhs-england-support-and-funding-for-cancer-alliances/</a></p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 168952 question first answered 11/09/2018 14:24:47 answering member 4067 label Biography information for Steve Brine
	tabling member	193 label Biography information for Dame Siobhain McDonagh

866427

	registered interest
	date	19/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care what assessment he has made of the effect of charging VAT on the affordability and accessibility of medicines.
	tabling member constituency	Brentford and Isleworth
	tabling member printed	Ruth Cadbury
	uin	904465
	answer	answer is ministerial correction date of answer 20/03/2018 answer text <p>Value Added Tax (VAT) paid by the National Health Service on the purchase of medicines is fully incorporated within the funding allocated to the NHS each year.</p><p>As is the case with many other goods and services, VAT is chargeable at 20% to members of the public when purchasing over the counter and non-prescription medicines.</p><p> </p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/03/2018 15:37:51 answering member 4067 label Biography information for Steve Brine
	tabling member	4389 label Biography information for Ruth Cadbury

867450

	registered interest
	date	20/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care what assessment his Department has made of the potential merits of providing additional funding for real-time continuous glucose monitoring.
	tabling member constituency	Hampstead and Kilburn
	tabling member printed	Tulip Siddiq
	uin	133425
	answer	answer is ministerial correction date of answer 28/03/2018 answer text <p>The Department has no plans to provide additional funding for real time glucose monitoring. NHS England is responsible for commissioning diabetes services and has informed us that, taking into account the overall impact on healthcare costs from improved control of diabetes, the overall costs from the use of continuous glucose monitoring can be lower than those that arise from self-monitoring. Therefore its provision can be cost effective without requiring additional investment. However, this cost-benefit analysis only holds true for particular cohorts of patients.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 28/03/2018 16:08:24 answering member 4067 label Biography information for Steve Brine
	tabling member	4518 label Biography information for Tulip Siddiq

867449

	registered interest
	date	20/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Medical Equipment
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care what estimate his Department has made of (a) the number of people with Type 1 diabetes who self-fund a real-time continuous glucose monitor in (i) each clinical commissioning group and (ii) England and (b) the annual cost to people of self-funding that monitoring for the most recent year for which data is available.
	tabling member constituency	Hampstead and Kilburn
	tabling member printed	Tulip Siddiq
	uin	133424
	answer	answer is ministerial correction date of answer 27/03/2018 answer text <p>The information requested is not centrally held.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 27/03/2018 11:50:54 answering member 4067 label Biography information for Steve Brine
	tabling member	4518 label Biography information for Tulip Siddiq

887927

	registered interest
	date	20/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diseases: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care what information his Department holds on levels of (a) breast cancer, (b) bowel cancer, (c) cervical cancer, (d) diabetic eye, (e) abdominal aortic aneurysm and (f) fetal anomaly screening in each year since those NHS screening programmes were introduced.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	136921
	answer	answer is ministerial correction date of answer 25/04/2018 answer text <p>The National Health Service Breast Screening Programme began in 1988. Data on the levels of Breast screening from 2004 to 2016 is available at:</p><p> </p><p><a href="https://digital.nhs.uk/data-and-information/publications/statistical/breast-screening-programme" target="_blank">https://digital.nhs.uk/data-and-information/publications/statistical/breast-screening-programme</a></p><p> </p><p>Data outside this time period are not available in the format requested.</p><p> </p><p>The NHS Cervical Screening Programme began in 1988. Data on the levels of Cervical screening from 2004 to 2016 are available at:</p><p> </p><p><a href="https://digital.nhs.uk/data-and-information/publications/statistical/cervical-screening-programme" target="_blank">https://digital.nhs.uk/data-and-information/publications/statistical/cervical-screening-programme</a></p><p> </p><p>Data outside this time period are not available in the format requested.</p><p> </p><p>The NHS Bowel Cancer Screening Programme started in 2006. Data for years 2016/17 are available in the following table. Data outside this time period are not available in the format requested.</p><p><strong> </strong></p><p>NHS bowel cancer screening data for 2016/17</p><table><tbody><tr><td><p>Indicator</p></td><td><p>Period</p></td><td><p>Rate for England</p></td></tr><tr><td><p>Persons, 60-69, screened for bowel cancer within six months of invitation (Uptake, %)</p></td><td><p>2016/17</p></td><td><p>57%</p></td></tr><tr><td><p>Persons, 60-69, screened for bowel cancer in the last 30 months (2.5 year coverage, %)</p></td><td><p>2016/17</p></td><td><p>57.4%</p></td></tr></tbody></table><p>Source: <a href="https://fingertips.phe.org.uk/search/cancer" target="_blank">https://fingertips.phe.org.uk/search/cancer</a></p><p> </p><p>The NHS Diabetic Eye Screening Programme began in 2007. Data for 2016/17 (by clinical commissioning group/region) are available here:</p><p> </p><p><a href="https://fingertips.phe.org.uk/search/DIABETIC%20EYE#page/3/gid/1/pat/46/par/E39000030/ati/152/are/E38000010/iid/92874/age/1/sex/4" target="_blank">https://fingertips.phe.org.uk/search/DIABETIC%20EYE#page/3/gid/1/pat/46/par/E39000030/ati/152/are/E38000010/iid/92874/age/1/sex/4</a></p><p> </p><p>Data outside this time period are not available in the format requested.</p><p> </p><p>The NHS Abdominal Aortic Aneurysm Screening Programme started in 2009. Data on coverage for 2016/17 (by region) are available here:</p><p> </p><p><a href="https://fingertips.phe.org.uk/search/Abdominal%20aortoa#pat/15/ati/6/par/E92000001" target="_blank">https://fingertips.phe.org.uk/search/Abdominal%20aortoa#pat/15/ati/6/par/E92000001</a></p><p> </p><p>Data outside this time period are not available in the format requested.</p><p> </p><p>The NHS Foetal Anomaly Screening Programme began in 2001. Data for 2016/17 are available in the Annual KPI data: April 2016 to March 2017 document here:</p><p> </p><p><a href="https://www.gov.uk/government/publications/nhs-screening-programmes-kpi-reports-and-briefings-2016-to-2017" target="_blank">https://www.gov.uk/government/publications/nhs-screening-programmes-kpi-reports-and-briefings-2016-to-2017</a></p><p> </p><p>A copy is attached. Data outside this time period are not available in the format requested.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 25/04/2018 16:19:31 answering member 4067 label Biography information for Steve Brine attachment 1 file name FA1 Fetal anomaly screening completion of laboratory request forms.xlsx title Foetal Anomaly Screening Programme data
	tabling member	1439 label Biography information for Norman Lamb

942538

	registered interest
	date	16/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Lumacaftor/ivacaftor
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care what plans he has to ensure his Department continues to engage and meet with NHS England and Vertex to discuss access to Orkambi.
	tabling member constituency	Thornbury and Yate
	tabling member printed	Luke Hall
	uin	164468
	answer	answer is ministerial correction date of answer 20/07/2018 answer text <p>NHS England has been in intensive discussions with Vertex to encourage it to price Orkambi at a level that would allow NHS England to fund its use without adversely impacting other patients. I and the Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy) have been keeping an extremely close eye on these discussions and wrote to Vertex in April, urging it to commit to pricing that is responsible and proportionate. I also re-iterated this message in the adjournment debate on 17 July, Official report, columns 383-4.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/07/2018 10:09:26 answering member 4067 label Biography information for Steve Brine
	tabling member	4450 label Biography information for Luke Hall